Rivers, Shannon M <br/><br/>
Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance.  [electronic resource] 

 -  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists   
 - 11-6 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1934-2403 
<br/><br/><label>Standard No.: </label>10.4158/EP.13.1.11  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Allylamine--administration & dosage<br/>Anticholesteremic Agents--administration & dosage<br/>Azetidines--administration & dosage<br/>Cholesterol, HDL--blood<br/>Cholesterol, LDL--blood<br/>Colesevelam Hydrochloride<br/>Diabetes Mellitus, Type 2--complications<br/>Drug Therapy, Combination<br/>Dyslipidemias--drug therapy<br/>Ezetimibe<br/>Female<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--adverse effects<br/>Male<br/>Metabolic Syndrome--complications<br/>Middle Aged<br/>Retrospective Studies<br/>Treatment Outcome